IP Library › Granted Patent US 9,962,424
Granted Patent B2
US 9,962,424 · App. 14/883,734 · Granted May 8, 2018

Use of antisecretory factors (AF) for optimizing cellular uptake

Inventors: Eva Jennische (Gothenburg, SE); Stefan Lange (Gothenburg, SE); Hans-Arne Hansson (Hovas, SE)
Assignee: LANTMÄNNEN AS-FAKTOR AB
A61K38/1709A61K31/704A61K35/57A61K45/06C07K7/04G01N2333/912G01N2500/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,962,424
App. No.
14/883,734
Granted
May 8, 2018
Kind
B2
Abstract

The present invention relates to the use of an antisecretory factor (AF) protein, peptide, derivative, homologue, and/or fragment thereof, having equivalent functional activity, and/or a pharmaceutically active salt thereof, for optimizing delivery and cellular uptake of a pharmaceutical substance and/or formulation, or a gene delivery. Typically, said pharmaceutical substance and/or formulation comprises an anticancer drug, radiation therapy, an antibiotic substance, an antiviral substance or a drug targeting posttraumatic injury, neurodegeneration, a parasite, or an inflammatory condition.

Claims (10)

1. A composition comprising the amino acid sequence consisting of SEQ ID NO: 4 or a pharmaceutically acceptable salt thereof in combination with a non-peptidic low molecular weight drug which is cytotoxic or cytostatic.

2. The composition of claim 1 , further comprising a pharmaceutically acceptable carrier or excipient.

3. The composition of claim 2 , wherein the pharmaceutically acceptable carrier or excipient is selected from the group consisting of a solvent, a buffering agent, a preservative, a chelating agent, an antioxidant, a stabilizer, an emulsifying agent, a suspending agent, a diluent, and a disintegrating agent.

4. The composition of claim 2 , wherein the pharmaceutically acceptable carrier or excipient comprises microspheres or liposomes.

5. The composition of claim 3 , wherein the solvent is selected from the group consisting of water, alcohol, blood, plasma, spinal fluid, ascites fluid, and lymph fluid.

6. The composition of claim 3 , wherein the buffering agent is selected from the group consisting of citric acid, acetic acid, tartaric acid, lactic acid, hydrogen phosphoric acid, bicarbonates, phosphates, and diethylamide.

7. The composition of claim 3 , wherein the chelating agent is EDTA or citric acid.

8. The composition of claim 3 , wherein the antioxidant is selected from the group consisting of butylated hydroxyl anisole (BHA), ascorbic acid and derivatives thereof, tocopherol and derivatives thereof, cysteine, and mixtures thereof.

9. The composition of claim 3 , wherein the diluent or disintegrating agent is selected from the group consisting of lactose, saccharose, emdex, calcium phosphates, calcium carbonate, calcium sulphate, mannitol, starches, and microcrystalline cellulose.

10. The composition of claim 3 , wherein the binding agent is selected from the group consisting of saccharose, sorbitol, gum acacia, sodium alginate, gelatin, chitosan, starches cellulose, carboxymethylcellulose, methylcellulose, hydroxyproplycellulose, polyvinylpyrrolidone, and polyethylene glycol.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2015
From: JENNISCHE, EVA; LANGE, STEFAN; HANSSON, HANS-ARNE
To: LANTMANNEN AS-FAKTOR AB
Reel/Frame 037284/0691 →
Priority Claims (1)
SE 0900170 · Feb 11, 2009 · national
Continuity (4)
Continuation 13148878
Continuation In Part 12289389 · Oct 27, 2008
Continuation PCTSE2007000413 · Apr 27, 2007
Related Publication 20160030515A1 · Feb 4, 2016